In today's Just The Facts.. Lindian Resources has hosted senior US Government officials at its Kangankunde rare earths project in Malawi, highlighting development progress and its potential role in supplying high-grade rare earths to global markets, amid growing US focus on securing critical mineral supply chains. Prescient Therapeutics has secured European authorisation to begin its PTX-100 clinical trial in Italy, enabling patient recruitment for a Phase 2a study in relapsed or refractory cutaneous T-cell lymphoma, as the company advances its first-in-class cancer therapy into Europe. Tamboran Resources has completed stimulation of its Shenandoah South 6H well in the Beetaloo Basin, with cost-saving optimisations applied, as the company prepares for flowback and a 30-day production test scheduled for early 2026. #RareEarths #CriticalMinerals #EnergyTransition #USSupplyChains #AfricaMining #Biotech #ClinicalTrials #Oncology #CancerResearch #TamboranResources #ASX #EnergyNews #NaturalGas #OilAndGas 查看留言
Just The Facts: Lindian Resources, Prescient Therapeutics, Tamboran Resources
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...